X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

KBI Biopharma Acquires Alliance Protein Laboratories, Expands Biophysical Capabilities

Yuvraj_pawp by Yuvraj_pawp
15th June 2017
in Market Moves

KBI Biopharma, Inc. (KBI) has agreed to acquire the assets of San Diego-based Alliance Protein Laboratories (Alliance), a leading analytical services company specializing in biophysical characterization of biopharmaceuticals.

Founded in 1998, Alliance is well known and highly regarded around the world for its expertise in characterization of therapeutic proteins, peptides, nucleic acids and vaccines.

Recognized as the foremost expert in analytical ultracentrifugation (AUC), an essential technology for determining physical stability, association state, molecular weight and quantitative characterization of protein aggregates, Alliance was also a pioneer in the use of biophysical methods to demonstrate that the higher order structure of biosimilar proteins and generic peptide therapeutics is comparable to the innovator product. Alliance has supported biosimilar developers since 2003, and has experience across an exceptionally broad range of biosimilar targets.


This acquisition will complement KBI’s extensive analytical and biophysical characterization capabilities, and expands those capabilities to include AUC. All of Alliance’s staff, including co-founders Tsutomu Arakawa, Ph.D. and John Philo, Ph.D. will join KBI through the acquisition with Tsutomu and John continuing to oversee operations in the San Diego-based laboratory.


This announcement marks another major expansion announced by KBI in 2017, starting with the addition of its cell therapy development and manufacturing operations in The Woodlands, TX this past February. In May, the company announced plans to expand its capabilities at both its Durham, NC and Boulder, CO facilities. On June 14, it was announced that parent company JSR Life Sciences would acquire Geneva-based Selexis SA to integrate with KBI to provide full gene to GMP solutions for clients.


“We are extremely excited to welcome Alliance Protein Labs, Dr. Philo and Dr. Arakawa to KBI Biopharma,” said KBI President Tim Kelly, Ph.D. “Alliance is a pioneer in the application of biophysical characterization to accelerate biopharmaceutical development, and their expertise in AUC, circular dichroism, light scattering and other techniques has earned the respect and admiration of our entire industry. The leadership of Tsutomu and John in San Diego adds an exciting new dimension for KBI to better serve our clients.”


“Alliance has found the ideal partner in KBI Biopharma,” said Alliance President Tsutomu Arakawa, Ph.D. “We can now offer our clients a much broader range of analytical characterization services in combination with KBI. KBI’s mission to accelerate biopharmaceutical development aligns perfectly with the core values that drive Alliance. John and I are thrilled to build on the success of Alliance by partnering with KBI.”


To date, KBI has helped to advance more than 300 molecules in 68 unique health indications. With the addition of these expanded analytical capabilities, and by adding a laboratory facility on the West Coast, KBI will continue to accelerate an even broader range of drug development programs for its global client base.


About KBI Biopharma

KBI Biopharma is a biopharmaceutical Contract Development & Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage biotech to academic/non-profit organizations to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.


KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapies for our clients.


KBI was founded in 1996 and operates 4 facilities: Durham and Research Triangle Park (NC), Boulder (CO), and The Woodlands (TX).
www.kbibiopharma.com

 

About Alliance Protein Laboratories

Alliance Protein Laboratories is a contract research and consulting firm specializing in biophysical analysis. It offers a broad range of biophysical characterization services, contract purification services (research scale), and consulting services.

Alliance was founded in 1998 by Drs. Tsutomu Arakawa and John Philo, and was the first CRO with a focus on biophysical analysis of proteins and peptides. Its laboratory is located in the heart of the biotechnology cluster in San Diego, CA. Clients include over 400 companies, universities and non-profit institutes in North America, Europe, Asia, and Australia.

http://www.ap-lab.com/

 

Contacts

JSR Life Sciences & KBI Biopharma, Inc.
Missy Bindseil
mbindseil@jsrlifesciences.com

Previous Post

FDA chooses Zepsyre from PharmaMar to explore potential development for pediatric cancers

Next Post

FierceBiotech’sDrug Development Forum Attracts Executive-Level Biopharma Professionals for Second Annual Conference in Boston This September

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post

FierceBiotech’sDrug Development Forum Attracts Executive-Level Biopharma Professionals for Second Annual Conference in Boston This September

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In